1.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
2.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
3.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
4.	Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C25003, 2011-005450-60, NCT01712490
5.	Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
6.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
7.	Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J0703, NA00005743, NCT00484874
8.	Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
9.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
10.	A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FDA IND 100712, NCT00611208
11.	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, NCT00918333
12.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
13.	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0981, NCI-2010-00235, 09-003801, RV-NHL-HL-PI-0466, CRAD001NUS113T, NCT01075321
14.	Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: PSOC 2502, NCI-2010-00907, NCT01165112
15.	Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-223-ST-001, NCT01177397
16.	Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 montha to 70 Sponsor: Other Protocol IDs: J1055, NA_00039823, NCT01203722
17.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
18.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
19.	A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AP26113-11-101, NCT01449461
20.	Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120003, 12-C-0003, NCT01468311
21.	Maintenance Lenalidomide in Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 11411, NCT01575860
22.	Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-203, NCT01609816
23.	Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-204, NCT01643603
24.	Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Phase: Phase II, Phase I Type: Treatment Status: Active Age: 13 to 60 Sponsor: NCI, Other Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
25.	CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2012-0265, NCT01664910